Modality
mRNA
MOA
Menini
Target
CD123
Pathway
Wnt
SLERSVSCLC
Development Pipeline
Preclinical
~Mar 2013
→ ~Jun 2014
Phase 1
~Sep 2014
→ ~Dec 2015
Phase 2
~Mar 2016
→ ~Jun 2017
Phase 3
Sep 2017
→ Jan 2029
Phase 3Current
NCT03918232
1,889 pts·SLE
2017-09→2029-01·Recruiting
1,889 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-282.8y awayPh3 Readout· SLE
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P3
Recruit…
Catalysts
Ph3 Readout
2029-01-28 · 2.8y away
SLE
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03918232 | Phase 3 | SLE | Recruiting | 1889 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| Zorizumab | Beam | Approved | CD123 | |
| Adagralucimab | Caribou Bio | NDA/BLA | CD123 | |
| TXG-6755 | 10x Genomics | Approved | CD123 | |
| Zoricapivasertib | CSL Limited | Phase 2 | HER2 |